HMGB1 mediates endogenous TLR2 activation and brain tumor regression - Test2 - elhamkhani - TriplyDB

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

http://www.wikidata.org/entity/Q27307459

about

The implication and potential applications of high-mobility group box 1 protein in breast cancer Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases Overview of current immunotherapeutic strategies for glioma Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications The role of mesenchymal stem cells in cancer development Gene therapy for brain tumors: basic developments and clinical implementation Dendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials Are BiTEs the "missing link" in cancer therapy?Toll-like receptor 4 enhancement of non-NMDA synaptic currents increases dentate excitability after brain injury.DNA alkylating therapy induces tumor regression through an HMGB1-mediated activation of innate immunity Alarmins: awaiting a clinical response Combined toll-like receptor 3/7/9 deficiency on host cells results in T-cell-dependent control of tumour growth Blocking TLR2 activity attenuates pulmonary metastases of tumor.Antiglioma immunological memory in response to conditional cytotoxic/immune-stimulatory gene therapy: humoral and cellular immunity lead to tumor regression Assessing the role of STAT3 in DC differentiation and autologous DC immunotherapy in mouse models of GBM Preclinical characterization of signal transducer and activator of transcription 3 small molecule inhibitors for primary and metastatic brain cancer therapy Human Flt3L generates dendritic cells from canine peripheral blood precursors: implications for a dog glioma clinical trial.High-mobility group box 1 and cancer.Toll-like receptor 2 and facial motoneuron survival after facial nerve axotomy.Kupfer-type immunological synapse characteristics do not predict anti-brain tumor cytolytic T-cell function in vivo.Single vs. combination immunotherapeutic strategies for glioma.Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail?Gene therapy for brain cancer: combination therapies provide enhanced efficacy and safety.A novel bicistronic high-capacity gutless adenovirus vector that drives constitutive expression of herpes simplex virus type 1 thymidine kinase and tet-inducible expression of Flt3L for glioma therapeutics Effects of single or combined treatments with radiation and chemotherapy on survival and danger signals expression in glioblastoma cell lines.EphrinA1-EphA2 interaction-mediated apoptosis and FMS-like tyrosine kinase 3 receptor ligand-induced immunotherapy inhibit tumor growth in a breast cancer mouse model Marmosets as a preclinical model for testing "off-label" use of doxycycline to turn on Flt3L expression from high-capacity adenovirus vectors.TLR4-mediated skin carcinogenesis is dependent on immune and radioresistant cells.Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastoma.Adenoviral vector-mediated gene therapy for gliomas: coming of age.Exogenous fms-like tyrosine kinase 3 ligand overrides brain immune privilege and facilitates recognition of a neo-antigen without causing autoimmune neuropathology Gene expression profiles of human glioblastomas are associated with both tumor cytogenetics and histopathology.Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma.Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway Toll-like receptors and cancer, particularly oral squamous cell carcinoma.Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity.Human herpesvirus 6 latent infection in patients with glioma.Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics.RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells.HMGB1 in health and disease.

P2860

Q26744069-66A0FC1B-FC26-44D0-A9F7-5086A763E5B2 Q26768480-86C1B7A4-8D90-434E-ABEB-11A2BB8196E4 Q26776345-9E98B955-09F2-4DC2-94E2-1C5D786FD004 Q26779221-D5E3C776-C064-4B36-8EA0-7341CA46A547 Q26823870-50D17E92-FE8F-473A-A8CC-164BED5D4975 Q26829086-6C18DE02-E4DD-4458-BD03-97E7273D837A Q27014829-0ABD3DFD-60AD-47A3-BCA5-EE460E85A28B Q28083907-B15AF6B4-1EEB-4666-A377-9D8E1872CA76 Q30392483-98AE59F9-FDDB-462C-9111-28B785AF7726 Q30499197-57BFE47C-9033-4DF7-A17E-628F00F57396 Q30523797-0072245A-B9F5-4D20-ABA9-F15646477BBA Q30842176-483EB65A-F4F5-4656-82CD-4EBB7DC3A7CE Q33490618-ED25A1AC-0759-4916-AF11-AC7140EA4EE3 Q33551268-245BFEF9-5931-4DDB-B89B-724C68FB268C Q33578030-2EF75A07-356F-4FEB-81A9-C4028B990EEC Q33603599-95FDA56E-D16A-497C-9306-7B808C3F0AC2 Q33605719-1BF7C655-E131-402A-8A76-9C6AA4DB7105 Q33638306-0951F169-831A-4767-B1A2-8A996048ED89 Q33673185-48FB1B23-1B33-46D6-88B9-880887E3C4A5 Q33740759-EE5E175F-7FBD-43D4-8A4A-A4D1734641C3 Q33746041-2C171C7C-E103-47DA-9850-147777167E6E Q33828102-C7EA4C42-E68A-4D23-AFDE-E3CEB8E7975A Q33828114-21025044-B11E-4FB8-A010-2F0C33376BA8 Q33877450-655DCE4C-31DB-4813-BEF6-4AC4F3C54D41 Q33908539-2A8EA589-C6D3-494E-A67B-E534205E5AAB Q33924763-D98E5335-8D62-4711-8EBE-E8BE2DF5A38C Q33950709-96691D1A-72BB-41AA-B5F1-7CF270500401 Q34000194-59F4268F-CB92-4551-9C7B-0F95F9C5A616 Q34012284-AB55E68A-80C1-4BAF-9C4C-86EF3FF6F0A5 Q34022048-BF3B0622-7927-4BDD-9389-0DB31BADA37C Q34069598-543E30CC-B610-4F8B-BF6D-5B88471BE8AC Q34116278-7B1F0BF2-F55B-4BCF-8801-C8EE0C38FD82 Q34208293-022420E9-E99B-44DE-81A9-BE1B28B487FD Q34227734-61AC1F81-EA19-4374-814E-348B2899473B Q34239239-B095D94B-5A58-42DD-97EE-E401E12642CC Q34287535-7C740413-BF22-4B5D-BC3B-8F62B4E7A6F3 Q34298606-428BF2CA-369A-4C09-BF9B-8D9D26774875 Q34359268-038A39F4-907D-4214-9112-AC736EEAA1BC Q34486464-12EBD012-5CD0-4763-A9AC-A9A1029FCD90 Q34622835-9FE698D7-172D-49E4-9481-418028A7598A

P2860

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

http://www.wikidata.org/entity/Q27307459

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

@ast

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

@en

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

@nl

type

label

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

@ast

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

@en

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

@nl

prefLabel

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

@ast

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

@en

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

@nl

P1433

Q27307459-2DF917E9-291B-496C-B9C9-EE744ADAAF6A

P1476

Q27307459-B7DBF37C-FD4D-455C-8579-E6C096956A1F

P2093

Q27307459-1D6CB6D8-AC1B-4D8B-A940-070DB37A5142

Q27307459-327BFB34-21BE-46BB-B609-4A9FAF348039

Q27307459-46BA1A86-33E8-4238-9118-E86D2BE1A821

Q27307459-6AF96764-B373-4B7C-9BC5-1947BE81FA37

Q27307459-8654C863-1929-4840-B95F-083474D4113F

Q27307459-8BC9AC0B-AA13-4A51-B9E5-135FABE406C0

Q27307459-A261E48E-B5F3-43BC-8C7B-5B5C8C24A12C

Q27307459-A7240DF4-454A-4BF7-A894-E134FF99F346

Q27307459-A8DBB788-0CAE-4F0D-8021-4D2B0D40CDA6

Q27307459-B5CFFB49-38EE-4A4D-AD2F-BB7E45BE3909

P2860

Q27307459-074CCE87-7BBF-43A1-BF2F-C445A251E881

Q27307459-0D95C9C5-152A-48C5-90BA-990752D6D247

Q27307459-0FCCB20A-B744-4800-9797-4CFA135BA99F

Q27307459-1BA9512C-CC8A-478D-B0B4-E8763BF1AD89

Q27307459-1C4AF7C6-F579-4763-87A8-6D31243EAB84

Q27307459-1CF90049-D348-4D9B-9B68-4839820C9675

Q27307459-24F74BBE-2E93-4B93-9D5F-3732DACD0FF9

Q27307459-2C19F3EE-914E-4784-B8AE-305D4C3728FD

Q27307459-3188C629-5C07-459D-8C28-40DAB63BB3DA

Q27307459-36390A25-9619-40D9-907E-3B864A5E8F28

P304

Q27307459-02F28BE1-FC97-4E42-8100-3A278AD05177

P31

Q27307459-51ABA8BB-8DFE-4043-9486-29D6A5220A65

P3181

Q27307459-311E0849-C8BB-4637-B347-5BAD0FC5628A

P356

Q27307459-8F67E262-8389-43AD-9A2C-12F08689A1E0

P407

Q27307459-BC19F933-78C1-411C-86FF-F589DEC7A2C5

P433

Q27307459-0C1ED1ED-CDE1-4BC1-8106-24B02107C6B3

P478

Q27307459-76E9BA4F-7954-4EDF-A960-3E137F606136

P50

Q27307459-657456EB-28A9-4855-BDF8-820C3527E90B

Q27307459-949ABBCA-7D88-41DC-A4E7-67629FA9142A

P577

Q27307459-696FF109-E999-45A3-B1D6-035309264F65

P5875

Q27307459-75E1D1D2-5CC3-4284-A00E-830522D0D6E7

P698

Q27307459-8F1512CE-9FCD-48E7-AE32-C1C40A3A8E45

P921

Q27307459-D081EDA4-AAA2-465F-B2A4-2DA8A50B93E6

Q27307459-D880BC6B-D0C1-4E77-9FF2-08427F671CF6

P932

Q27307459-71C5C4B3-8274-48D1-8CFB-C1D6B9FE2BA8

P3181

P356

JOURNAL.PMED.1000010

P1433

P1476

HMGB1 mediates endogenous TLR2 activation and brain tumor regression

@en

P2093

A K M Ghulam Muhammad

http://www.w3.org/2001/XMLSchema#string

Begonya Comin-Anduix

http://www.w3.org/2001/XMLSchema#string

Chunyan Liu

http://www.w3.org/2001/XMLSchema#string

Hikmat Assi

http://www.w3.org/2001/XMLSchema#string

James F Curtin

http://www.w3.org/2001/XMLSchema#string

Kader Yagiz

http://www.w3.org/2001/XMLSchema#string

Kathrin S Michelsen

http://www.w3.org/2001/XMLSchema#string

Kurt M Kroeger

http://www.w3.org/2001/XMLSchema#string

Maria G Castro

http://www.w3.org/2001/XMLSchema#string

Marianela Candolfi

http://www.w3.org/2001/XMLSchema#string

P2860

Inflammation and cancer: The oncogene-driven connection

Pathogen recognition and innate immunity

HMG-1 as a late mediator of endotoxin lethality in mice

The danger model: a renewed sense of self

Treatment with HMGB1 inhibitors diminishes CTL-induced liver disease in HBV transgenic mice

The secretion of HMGB1 is required for the migration of maturing dendritic cells

Interactions of sequence variants in interleukin-1 receptor-associated kinase4 and the toll-like receptor 6-1-10 gene cluster increase prostate cancer risk

Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components

Expression and release of CD14 in astrocytic brain tumors

Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex

P304

e10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4849195

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PMED.1000010

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23787628

http://www.w3.org/2001/XMLSchema#string

P698

19143470

http://www.w3.org/2001/XMLSchema#string

P921

Toll-like receptor

P932

2621261

http://www.w3.org/2001/XMLSchema#string